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Abstract
Background: Lysosomal protein transmembrane 4 beta (LAPTM4B) is a gene related to hepatocellular carcinoma that has
two alleles designated LAPTM4B*1 and LAPTM4B*2. This study aimed to investigate the correlation of LAPTM4B genotype
with prognosis and clinicopathologic features in patients who have undergone resection for hepatocellular carcinoma
(HCC).
Methodology/Principal Findings: The LAPTM4B genotype was analyzed by PCR in 68 patients who had undergone curative
hepatic resection for hepatocellular carcinoma. The correlation of LAPTM4B genotype with clinicopathologic parameters
was assessed with the Chi-squared test. Differences in patient survival were determined by the Kaplan–Meier method.
Multivariate analysis of prognostic factors was carried out with Cox regression analysis. Patients with LAPTM4B *2 had both
significantly shorter overall survival (OS) and shorter disease-free survival (DFS) (both P,0.001). Multivariate analysis showed
that LAPTM4B genotype is an independent prognostic factor for OS and DFS (both P,0.001).
Conclusions/Significance: Allele *2 of LAPTM4B is a risk factor associated with poor prognosis in patients with resected
HCC. LAPTM4B status may be useful preoperatively as an adjunct in evaluation of the operability of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer death in the world and is the most common cause
of cancer death in China [1–4]. There are many risk factors which
are associated with HCC and contribute to transformation of liver
cells. These factors include alcohol, hepatitis B and C virus and
conditions such as cirrhosis [5,6]. However these risk factors for
the most part have not been of clinical value in predicting patient
survival or in evaluating operability of HCC. It would therefore be
beneficial for selection of therapy in these patients to find markers
which predict prognosis in HCC.
Lysosomal protein transmembrane-4 beta was originally cloned
from HCC in our laboratory, and this gene resides at 8q22.1 and
contains seven exons [7]. Previous studies have demonstrated that
LAPTM4B mRNA and protein are significantly up-regulated in a
wide variety of cancers such as lung cancer, gallbladder
carcinoma, extra-hepatic cholangiocarcinoma, cervical carcino-
ma, colon cancer and ovarian cancer [8–13]. The LAPTM4B
gene is amplified in many breast cancers and its amplification is
related to breast carcinoma recurrence [14]. Moreover, transfec-
tion of LAPTM4B cDNA results in overexpression of LAPTM4B
which is associated with promotion of HCC cell invasion in nude
mice xenografts, as well as with other malignant phenotypic
features such as cell proliferation and migration, and multidrug
resistance [15–18]. Conversely knockdown of LAPTM4B by RNA
interference reverses multiple malignant phenotypes [16]. These
observations and data argue that this gene plays a fundamental
role in many types of neoplasia, and previous studies have shown
that LAPTM4B protein is overexpressed in HCC, and this
overexpression is significantly correlated with tumor histopatho-
logical grade and prognosis. This has led us to consider whether it
could serve as a prognostic marker in patients under evaluation for
resection of HCC.
The LAPTM4B gene has two alleles designated LAPTM4B*1
and LAPTM4B*2 (GenBank No. AY219176 and AY219177).
Allele *1 contains only one copy of a 19-bp sequence, whereas this
sequence is duplicated and tandemly arranged in allele *2 in the
first exon of the LAPTM4B gene [19–24]. As reported in our
previous study, we found that the allelic frequencies of the
LAPTM4B*2 allele were 38.24% in the HCC group and 24.07%
in the control group, representing a significant different between
these two groups (P,0.001), and suggesting that the LAPTM4B*2
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lular carcinoma [23]. The existence of two LAPTM4B gene
variant alleles raises the possibility that prognosis in HCC may be
related to gene polymorphism. The present work therefore aimed
to investigate whether there is a correlation of LAPTM4B gene
polymorphism with prognosis in HCC patients who have
undergone surgical resection. In order to investigate this
relationship, we evaluated the genotype of patients who have
had HCC surgery for attempted curative resection, and our results
show that LAPTM4B allelic variation is significantly associated
with prognosis in these patients. LAPTM4B genotype may
therefore be a marker for HCC prognosis and might serve as an
adjunct marker for preoperative evaluation.
Materials and Methods
Patients
Blood samples were obtained from 68 HCC patients who were
hospitalized and underwent surgical resection in Third Hospital
Affiliated to Peking University from January 2002 to December
2009. All patients who had attempted curative resection for HCC
in Third Hospital during this period were included in this study
and there were no other selection criteria for inclusion other than
availability of follow up information.
There are 57 male patients and 11 female patients in this study,
which is not unexpected as M:F ratios in areas of high HCC incidence
may be as high as 8:1 (Robbins Basic Pathology, 7th edition, 2003),
and the mean patient age was 51.7 (range 29–80). TNM staging was
carried out for each patient according to AJCC-UICC guidelines
(AJCC_UICC, 5th edition, 1997), and clinical hepatic status was
determined according to standard criteria (Liver Pathology, Churchill
Livingstone Publishing House, New York, 1986).
Patient clinicopathologic features, which include history of
hepatic viral infection, size of tumor, presence or absence of portal
vein invasion, histopathologic tumor differentiation, and serum
AFP level, together with TNM stage and presence or absence of
tumor recurrence are summarized (Table 1). The Institutional
Ethics Committee of Peking University approved this study before
investigation was begun, and every patient gave informed consent
for participation.
DNA extraction
Human peripheral blood samples were collected in EDTA tubes
and kept at 220uC. Blood was thawed in a water bath at room
temperature and genomic DNA was isolated from 200 ul of each
blood sample using the NucleoSpin Blood genomic DNA
extraction kit (Macherey-Nagel, Duren, Germany) for PCR assay.
PCR analysis
LAPTM4B genotype was determined by PCR analysis using the
specific primers F (forward): 59 GCCGACTAGGG-
GACTGGCGGA 39 (nt 72–92) and R (reverse): 59 CGA-
GAGCTCCGAGCTTCTGCC 39 (nt 255–275). PCR assay was
carried out in a 20 ul reaction mixture containing 0.5 U Taq
DNA polymerase (NEB, Beijing, China) using 1 ul of template
DNA of 100 ng/ul. The PCR conditions were 95uC denaturation
for 5 min, 35 cycles of 30 s at 94uC, 30 s at 60uC and 30 s at
72uC, followed by extension at 72uC for 10 min. PCR products
were analyzed by electrophoresis in a 2% agarose gel and
visualized with ethidium bromide.
Statistical analysis
The Chi-square test was used to demonstrate differences in the
genotypic distribution of LAPTM4B and categorical variables.
The Kaplan–Meier method and log-rank test were used to
evaluate differences in patient overall survival and disease-free
survival. Disease-free survival was defined as the interval from the
time of surgery until any sign of tumor recurrence or metastasis
was found during patient follow up clinical examination. Potential
prognostic factors were subjected to multivariate analysis using
Cox regression analysis (Proportional hazard model). SPSS10.0
software (SPSS Inc., Chicago, IL) was used for all statistical
analysis. P values,0.05 were defined as statistically significant.
Results
Genotypes of the LAPTM4B gene
Three different genotypic LAPTM4B polymorphisms designat-
ed LAPTM4B*1, LAPTM4B*2 and LAPTM4B*1/*2 were
identified by PCR assay. As shown in Figure 1, genotypes *1/1
Table 1. Relationship between LAPTM4B genotypes and









Male 57 16 32 9
Female 11 6 3 2
Age (years) 0.415
,65 44 14 21 9
$65 24 8 14 2
Viral status 0.171
Hepatitis virus B 49 16 22 11
Hepatitis virus C 12 3 9 0
Both hepatitis virus B and C 2 0 2 0
Non-B, Non-C 5 3 2 0
Tumor size 0.852
,5c m 3 7 1 3 1 8 6
$5 cm 31 9 17 5
portal vein invasion 0.001
No 49 22 22 5
Yes 19 0 13 6
Histopathological differentiation 0.009
WD 20 12 6 2
MD 25 8 14 3
PD 23 2 15 6
Serum AFP level 0.144
,25 ng/ml 35 14 18 3
$25 ng/ml 33 8 17 8
TNM stage ,0.001
I–II 23 18 4 1
III–IV 45 4 31 10
Recurrence ,0.001
No 17 12 5 0
Yes 51 10 30 11
LAPTM4B, Lysosomal protein transmembrane 4 beta; HCC, hepatocellular
carcinoma; a, Chi-square test.
doi:10.1371/journal.pone.0034984.t001
LAPTM4B Gene Polymorphism and HCC
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band, and genotype *1/*2 shows both of these bands. All bands
were identified with PCR using specific primers and separated by
electrophoresis on a 2% agarose gel.
Genotypes of LAPTM4B and clinical parameters
These 68 patients who underwent hepatic resection at Third
hospital affiliated with Peking University from 2002 to 2009 were
followed clinically for periods ranging from 2 to 92 months
(average 33 months). At the end date for follow up (December 31,
2010), 16 patients (23.5%) were alive, and 52 (76.5%) had died of
disease. We found that genotype *2 of the LAPTM4B gene was
significantly associated with recurrence, poor histopathologic
differentiation, higher TNM stage and portal vein invasion
(Table 1; P,0.05), but not with viral infection status, tumor size
or serum AFP level, age or gender (Table 1; P.0.05).
LAPTM4B genotype and HCC prognosis
Using the Kaplan–Meier method and the log-rank test,
genotype *2 of the LAPTM4B gene showed correlation both with
shorter disease-free survival and shorter overall survival in the 68
patients who underwent curative resection for HCC (Fig. 2A and
B, and Table 2; both P,0.001). In addition, as expected survival
benefit was also found in patients with lower TNM stage, lower
grade histopathologic differentiation and absence of portal vein
invasion both for overall and disease-free survival (Table 2;
P,0.05). No other clinicopathologic features showed predictive
value in this analysis (Table 2; P.0.05).
LAPTM4B genotype is an independent prognostic maker
in patients who have undergone curative resection for
HCC
Multivariate Cox regression analysis revealed that LAPTM4B
genotype (RR, 3.147, 95%CI, 1.619–6.115, P=0.001) and portal
vein invasion (RR, 3.542, 95%CI, 1.752–7.158, P,0.001) are
independent prognostic markers for overall survival of patients
with HCC (Table 3; P,0.05). LAPTM4B genotype (RR, 2.729,
95%CI, 1.427–5.220, P=0.002) and portal vein invasion (RR,
2.953, 95%CI, 1.437–6.068, P=0.003) are also independent
prognostic markers for disease-free survival of patients with HCC
(Table 3; P,0.05).
Discussion
In this study, we tested LAPTM4B genotype by PCR assay in
68 patients who had surgical resection for hepatocellular
carcinoma. We found that LAPTM4B *2 is significantly correlated
with recurrence, higher TNM stage and invasion of the portal
vein, but this allele showed no relationship to patient liver status,
histopathologic tumor grade, viral status, size of tumor, serum AFP
level gender or patient age. Moreover, patients with LAPTM4B *2
(alleles *2/2 or *1/2) had significantly poorer overall survival (OS)
and disease- free survival (DFS) as compared to patients with
LAPTM4B *1/1.
This is the first time correlation of LAPTM4B genotype both
with prognosis and clinicopathologic features has been demon-
strated in hepatocellar carcinoma. This association of genotype
with clinicopathologic findings and prognosis is consistent with the
putative role LAPTM4B plays in carcinogenesis and tumor
progression. Previous studies which have shown upregulation
and/or amplification of the LAPTM4B gene in a variety of human
cancers, and this together with experimental evidence showing
malignant phenotypic features can be induced or reversed by
transfection or knockdown respectively of LAPTM4B strongly
suggests that this gene plays a fundamental role in the neoplastic
mechanism(s) of these tumors [17,25,26]. There are some recent
findings which may in part serve to illustrate how LAPTM4B
functions in tumors which harbor this gene. For example,
overexpression of LAPTM4B may activate the AKT signaling
pathway and proto-oncogenes including c-fos, c-myc, and c-jun
and thus promote malignant transformation. In addition, knock-
down of LAPTM4B or mutation of the PPRP motif in the N-
terminal region of LAPTM4B attenuates its roles in tumorigenesis
and metastasis [26].
The allele LAPTM4B*1 (GenBank No. AY219176) differs from
allele LAPTM4B*2 (GenBank No. AY219177) in that it contains a
particular single 19-bp sequence, whereas LAPTM4B *2 contains
two of these sequences in a tight tandem array in the 59 UTR of
exon 1. The allelic frequencies of the *2 allele were 33.9%, 33.2%,
and 40.1% in individuals with gastric, colon, and lung cancer,
respectively, which were significantly higher than those of
corresponding healthy controls [21,22]. LAPTM4B*1 produces
a 35 kD protein while LAPTM4B*2 produces a 40 kD protein
with an extra 53 amino acids at the N terminus which are not
present in the protein produced by LAPTM4B*1. This difference
in proteins is due to the 19-bp difference in the first exon of the
gene which alters the ORF. Previous studies have shown that
LAPTM4B polymorphisms are associated with increased risk for
gastric cancer and cervical cancer in Chinese patients. In view of
the latter and given the extensive evidence of LAPTM4B’s
involvement in neoplasia, as well as its demonstrated relation to
histologic grade and tumor recurrence in some cancers, it is likely
that this 19-bp sequence plays an important role in genetic
transcriptional regulation or that the extra 53 amino acids at the N
terminus produced by LAPTM4B* 2 may influence physiological
activity and function in tumor cells.
Hepatocellular carcinoma is a major health problem, and is the
leading cause of death from cancer worldwide. Although the exact
molecular mechanisms which underlie the function of LAPTM4B
in hepatocarcinogenesis have not as yet been worked out,
LAPTM4B*2 may be an oncogene or play an important role in
cell cycle control. However, LAPTM4B *2 is significantly
associated with tumor recurrence, poor histopathologic differen-
tiation, higher TNM stage and presence of portal vein invasion
which argues that it is a driver of hepatocellular carcinoma and
therefore warrants further investigation. In addition, it is an
independent prognostic factor for postoperative survival in patients
who have undergone curative surgical resection for HCC. It is
likely that the relatively high overall failure rate in surgical
intervention for HCC is at least in part due to imprecision in
preoperative staging. Therefore, it is possible that LAPTM4B *2
will be useful as an adjunct for evaluation of HCC prior to
embarking upon curative surgical resection. Figure 1. LAPTM4B genotyping. Analysis by separation with 2%
agarose gel electrophoresis. Lanes 1, 3: genotype*1/2; lane 2:
genotype*1/1; lane 4: genotype *2/2.
doi:10.1371/journal.pone.0034984.g001
LAPTM4B Gene Polymorphism and HCC
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genotype *1/1, black solid line; LAPTM4B genotype *1/2, black dashed line; LAPTM4B genotype *2/2, grey solid line. (A) Overall survival after surgery.
(B) Disease-free survival after surgery.
doi:10.1371/journal.pone.0034984.g002
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Mean±SE (month) 95% CI P
a Mean±SE (month) 95% CI P
a
Gender 0.476 0.403
Male 57 3965 (30–48) 3165 (22–40)
Female 11 3867 (24–51) 3567 (21–49)
Age(years) 0.456 0.769
,65 44 3865 (28–48) 3365 (22–43)
$65 24 3866 (27–50) 3266 (20–44)
Viral status 0.182 0.359
Hepatitis virus B 49 3765 (28–47) 3065 (21–39)
Hepatitis virus C 12 40610 (20–60) 35611 (14–57)
Both hepatitis virus B and C 2 19610 (0–37) 964 (2–15)
Non-B, Non-C 5 62611 (40–83) 54611 (33–76)
Tumor size 0.665 0.749
,5c m 3 7 4 1 66 (30–52) 3466 (23–45)
$5c m 3 1 3 8 66 (26–50) 3266 (19–44)
portal vein invasion ,0.001 ,0.001
No 49 5165 (41–61) 4365 (33–53)
Yes 19 1261 (10–15) 761 (5–10)
Histopathological differentiation 0.003 0.005
WD 20 5768 (41–73) 4768 (32–62)
MD 25 3765 (26–47) 3266 (21–43)
PD 23 2365 (13–32) 1665 (6–26)
Serum AFP level 0.233 0.208
,25 ng/ml 35 4566 (33–57) 3866 (26–49)
$25 ng/ml 33 3164 (22–39) 2565 (15–34)
TNM stage ,0.001 ,0.001
I–II 23 7367 (60–86) 6467 (51–77)
III–IV 45 2363 (17–30) 1764 (11–24)
LAPTM4B genotypes ,0.001 ,0.001
*1/1 22 7566 (64–86) 6666 (55–78)
*1/2 35 2764 (18–35) 2165 (12–30)
*2/2 11 1161 (10–12) 460 (4–5)
LAPTM4B, Lysosomal protein transmembrane 4 beta; HCC, hepatocellular carcinoma; OS, overall survival; DFS, disease-free survival; a, Log-rank test.
doi:10.1371/journal.pone.0034984.t002
Table 3. Multivariate Survival Analysis of OS and DFS in 68 patients with HCC.
Variables OS DFS
RR 95%CI P
a RR 95%CI P
a
TNM stage 2.482 (1.003–6.143) 0.049 1.905 (0.868–4.181) 0.108
Portal vein invasion 3.542 (1.752–7.158) ,0.001 2.953 (1.437–6.068) 0.003
Histopathological differentiation 1.325 (0.861–2.037) 0.200 1.336 (0.888–2.010) 0.165
LAPTM4B genotype 3.147 (1.619–6.115) 0.001 2.729 (1.427–5.220) 0.002
LAPTM4B, Lysosomal protein transmembrane 4 beta; HCC, hepatocellular carcinoma; OS, overall survival; DFS, disease-free survival; RR, relative risk; CI, confidence
interval; a,Cox regression test.
doi:10.1371/journal.pone.0034984.t003
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